Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.

Albert K Park¹, Jason Hom¹, Javier Lorenzo², Vidya Rao², Gavin Hui³, Matthew Vickers⁴, Neera Ahuja¹

¹Department of Medicine, Stanford University Medical Center, Stanford, California, USA.

²Department of Anesthesiology, Perioperative and Pain Medicine, Division of Anesthesia Critical Care, Stanford University Medical Center, Stanford, California, USA.

³Atropos Health, Palo Alto, California, USA.

⁴Eucalyptus, Sydney, Australia.

PubMed DOI

Abstract

BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes. GLP-1 agonists influence body composition through effects on both fat mass and fat-free mass. Given that critically ill patients experience severe protein catabolism and commonly develop intensive care unit (ICU)-acquired weakness, questions arise about outcomes when metabolic demands…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.